Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIME Trial: Chronotherapy with Nivolumab and Ipilimumab in Melanoma
NCT07155317Phase 2Recruiting
- Sponsor
- Emory University
- Start
- Oct 2025
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab, ipilimumab in melanoma, sponsored by Emory University. Started Oct 2025; status: recruiting.
02
Drugs
nivolumabipilimumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT07155317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07155317.